While actual clinical implementation remains distant, MALDI imaging technology has advanced to the point where it might feasibly be applied to pathology.
Bioinformatics firm Berg is combining multi-omics data from the Department of Defense's Center for Prostate Disease Research in search of biomarkers.
The company's validation studies demonstrate that the assay has a 99 percent negative predictive value, which it believes will persuade physicians of its value.
Asia Genomics will make CellMax's tests, including the CellMax-DNA Genetic Cancer Risk Test Assure and the CellMax-CRC Protect Test, available immediately.
The company has contracted IPS Genomix to distribute the SelectMDx test in Lebanon, Egypt, the UAE, Saudi Arabia, Oman, Bahrain, Qatar, and Jordan.
A small study of prostate cancers from African American and European American men uncovered ancestry-associated splicing with apparent ties to tumor aggressiveness and resistance.
The tests were previously available in New York state on a patient-by-patient basis through a non-permitted laboratory testing program.
Using array-based miRNA profiles for individuals treated for prostate cancer, researchers identified 37 miRNA with differential expression in cases with recurrence.
Results of a new study offer preliminary evidence that blood tests could select patients for treatment, and track response and resistance.
The Department of Veterans Affairs is leaning on the Department of Energy's supercomputing platform to crunch genomic and health data.
Gene drives might run into biological resistance, the Economist reports.
Forensic experts exhumed painter Salvador Dalí's body to collect DNA for a paternity test, CBS News reports.
Yale Environment 360 writes that synthetic and conservation biologists aren't always on the same wavelength, but they are trying to reach an understanding.
In Science this week: full CRISPR locus integration complex structure, and more.